Medication

Search for

Medication research papers

Decision Support for Treatment of Patients with Advanced Parkinson's DiseaseThe overall aim of this thesis was to develop, deploy and evaluate new IT-based methods for supporting treatment and assessment of treatment of advanced Parkinson's disease. 23 October 2013
Urinary profile of catecholamines and metabolites in Parkinson patients with deep brain stimulationConclusion: After DBS-STN, the DA/l-DOPA ratio, an indirect measure of DA synthesis, increased. These results show that DBS-STN may improve the efficacy of oral levodopa. 16 May 2013
Variability in neuronal expression of dopamine receptors and transporters in the substantia nigraRecent studies have suggested that alterations in dopamine receptors in the midbrain underlie impulsive behaviors and that more impulsive individuals, including patients with PD, exhibit increased occupancy of their midbrain dopamine receptors. 14 May 2013
Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's: pharmacokinetic & clinical consideratioSerum vitamin D concentrations were correlated inversely with Parkinson's severity, as measured by the motor Unified Parkinson's Disease Rating Scale. Among the balance measures, vitamin D concentrations were correlated with automatic posture responses to backwards translation, specifically with response strength and stance weight asymmetry. 06 May 2013
Initial Treatment of Parkinson's Disease: An UpdateThis review touches on the clinical research into the benefits of exercise in PD, and briefly review some of the current studies for new formulations of levodopa and other medications and treatments with novel mechanisms of action. 04 May 2013
Levodopa changes the severity of freezing in Parkinson's diseaseAuthors evaluated the gait phenomenology of 20 Parkinson's disease patients with freezing of gait before and 60 min after a standardized levodopa dose using a rating scale based on the assumption that festination and akinetic freezing share a common pathophysiology. 03 May 2013
Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeysSafinamide and amantadine reduced LID in this primate model while only safinamide increased the duration of the antiparkinsonian response of l-DOPA, suggesting that safinamide may have effects on LID that are pharmacologically distinct from amantadine, which is in current clinical use for control of LID. 01 May 2013
Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal deliveryProspective, large-scale, long-term studies are needed to clarify whether vitamin supplementation and routine use of a catechol-O-methyltransferase inhibitor may help prevent PN in LCIG recipients and whether these measures should be routine practice in patients with PD on high-dose oral levodopa. 01 May 2013
Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot studyConclusions: Memantine treatment was associated with lower axial motor symptom and dyskinesia scores but did not improve gait. These benefits must be confirmed in a broader population of patients. 01 May 2013
Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's diseaseIn the current study, the STRIDE-PD study population was investigated to determine the effect of l-dopa dose and other risk factors on the development of dyskinesia and wearing-off. Patients were randomized to receive LCE (n=373) or LC (n=372). 29 April 2013

Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [+11]

[ Next » ]